In tablet lines handling silibinin pharma grade API, the principal processing constraint is the low aqueous solubility of the flavonolignan mixture—silybin A and silybin B—reported below 0.05 mg/mL in unbuffered water at 25°C. The API is generally treated as a BCS Class II/IV compound, meaning dissolution rather than permeation often controls oral absorption. For immediate-release film-coated tablets with a nominal silibinin content of 70 mg or 140 mg per unit, the formulation addition ratio is maintained between 40% w/w and 55% w/w of the uncoated core mass, with the remainder comprising microcrystalline cellulose PH 102, crospovidone, povidone K 30, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. The batch record is designed to comply with ICH Q3C for residual solvents, ICH Q3D for elemental impurities, USP <905> for uniformity of dosage units, USP <711> for dissolution, and USP <1216> for friability. Dissolution testing uses apparatus 2 at 50 rpm in 900 mL of 0.1 M HCl containing 0.5% sodium lauryl sulfate at 37°C ± 0.5°C; the surfactant is required to maintain a discriminatory release profile across batches because the uncomplexed API is practically insoluble in purely aqueous acidic media.

Downstream production on a conventional oral solid line uses a top-driven high-shear granulator equipped with an impeller and chopper. Silibinin is pre-blended with microcrystalline cellulose and crospovidone for 10 minutes at impeller speed 250 rpm, then granulated with an aqueous povidone binder solution added at 8–12% w/w of dry powder mass. Wet massing time is kept between 4 minutes and 6 minutes; over-massing increases granule density and shifts the dissolution curve to the right, while under-massing leaves a high fraction of ungranulated API and raises tablet friability. The wet granules are dried in a fluid-bed dryer with inlet air temperature 55–65°C and product temperature not exceeding 40°C to a final loss-on-drying of 1.8–2.4%. The dried granulate is milled through a 0.8 mm conical screen and blended with croscarmellose sodium for 10 minutes, then lubricated with magnesium stearate for 3 minutes. Over-lubrication beyond 5 minutes is avoided because the resulting hydrophobic film on granules retards disintegration and can delay release. Compression is performed on a rotary tablet press fitted with 8 mm round concave punches at 10–15 kN compression force, targeting hardness 70–100 N and friability below 1.0%. The cores are film-coated with a hypromellose-based system in a side-vented pan at 2.5–3.5% weight gain. Terminal products are biconvex film-coated tablets of 70 mg and 140 mg silibinin, packed in aluminium-PVC/PVDC blisters under storage at 25°C and 60% RH.

What Happens When Silibinin Is Co-Processed with Phosphatidylcholine for Hard Capsule Systems?

Co-processing silibinin with phosphatidylcholine is used to increase oral bioavailability without changing the terminal capsule format. The addition ratio in this downstream scenario is expressed as complex mass rather than free silibinin: a silibinin-phosphatidylcholine complex containing approximately 30% w/w silibinin is filled at unit doses of 80 mg or 120 mg silibinin equivalent, corresponding to 267 mg or 400 mg complex per capsule. The powder fill typically contains 65–75% w/w complex, microcrystalline cellulose PH 102, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate, with nominal fill weights of 320–360 mg in size 1 or size 0 capsules. Compliance for this dosage form is governed by ICH Q1A(R2) for stability, ICH Q6A for specification setting, USP <711> for dissolution, USP <904> for disintegration, and USP <61> / <62> for microbial limits. If the complex is manufactured as an amorphous solid dispersion, X-ray powder diffraction is used as a release test to confirm the absence of crystalline silibinin, and the complex specification includes residual solvent limits under ICH Q3C.

The downstream process begins with the complex, which is either dry-mixed or granulated depending on its bulk density and flow. In a typical capsule line, the complex is blended with microcrystalline cellulose and croscarmellose sodium in a bin blender for 15 minutes, then lubricated with magnesium stearate for 3 minutes. The mixture is filled on an automatic dosator-type capsule filling machine at 55–75% relative humidity, because the complex becomes tacky above 60% RH and capsule shells can soften above 65% RH. If powder build-up on dosator pins is observed, the filling speed is reduced and the powder bed is conditioned with dry air. Disintegration time targets not more than 15 minutes in water at 37°C ± 2°C per USP <701>. Dissolution testing typically uses USP apparatus 2 at 50 rpm in 900 mL of 0.1 M HCl containing 0.5% sodium lauryl sulfate or in phosphate buffer pH 6.8 with surfactant, depending on the label claim and compendial scope. Terminal products are hard gelatin or hypromellose capsules containing 80 mg or 120 mg silibinin equivalent as silibinin-phosphatidylcholine complex, administered with food to reduce first-pass variability.

Granule-filled sachets are used where dose titration, swallowing difficulty, or body-weight-adjusted dosing creates a need for a divisible oral solid. Silibinin pharma grade API in this downstream format is dispersed in an aqueous binder system and sprayed onto a mannitol and maltodextrin carrier in a fluid-bed granulator. The addition ratio is lower than in tablets: silibinin is typically present at 2.5–4.0% w/w of the final granule mass, corresponding to 50 mg or 100 mg silibinin in a 2.0 g or 2.5 g sachet. Granulation is performed as a top-spray process with inlet air temperature at 50–60°C, product temperature 30–38°C, spray rate 8–12 g/min per kg batch, and atomising air pressure 1.5–2.0 bar. The binder phase is an aqueous solution of povidone K 30 and maltodextrin DE 18–20; silibinin is suspended in the binder phase to avoid segregation and to ensure content uniformity of the low-dose granule. After spraying, granules are dried to a moisture content of 1.5–2.5% and screened through a 1.0 mm sieve; target particle size is D50 150–250 µm with D90 ≤ 500 µm.

Compliance for this format follows Ph. Eur. 2.9.12 for powder flow and sieve analysis, USP <786> for particle size distribution, USP <905> for uniformity of dosage units, USP <711> for dissolution, and ICH Q3C / Q3D for residual solvents and elemental impurities. Published production-scale data for silibinin oral granules are more limited than for tablet and capsule forms; the parameters stated above reflect low-dose granulation practice and must be verified against product-specific stability data. Organoleptic controls are required because silibinin is bitter; granular formulations frequently use a mannitol and maltodextrin matrix with a non-alkaline flavour system and may require film-coated API or cyclodextrin complexation if acceptable taste cannot be achieved by sweetness and flavour masking alone. Terminal products are stick-pack or three-side-seal sachets containing 50 mg or 100 mg silibinin per unit, with a dispersion time in water at 25°C of ≤ 2 minutes; sachet film is a light-resistant laminate because silibinin is prone to photodegradation.

Lyophilised Silibinin Succinate: Aseptic Filtration and Freeze-Drying Boundary Conditions

Intravenous silibinin is marketed as a lyophilised powder for solution for infusion containing 528.5 mg silibinin-C-2',3'-dihydrogen succinate disodium salt equivalent to 350 mg silibinin per vial. The addition ratio in the lyophilisation feed solution is generally 50–60 mg/mL of the succinate salt in Water for Injection, with pH adjustment to 7.0–7.5 using dilute sodium hydroxide or a phosphate buffer. The solution is sterile-filtered through a 0.22 µm PVDF membrane; the filter is integrity-tested before and after use by bubble point and diffusion flow. The filtered solution is filled into 10 mL Type I borosilicate glass vials at a fill volume of 6–7 mL and partially stoppered with bromobutyl rubber closures. Regulatory compliance in this downstream segment includes EU GMP Annex 1 for aseptic processing and lyophilisation, USP <71> and Ph. Eur. 2.6.1 for sterility, USP <85> and Ph. Eur. 2.6.14 for bacterial endotoxins, USP <788> and Ph. Eur. 2.9.19 for sub-visible particulate matter, and USP <660> for glass container suitability.

The lyophilisation cycle is the main process control point. Product temperature must remain below the collapse temperature of the formulation, which is typically between -25°C and -30°C for this matrix; a conservative cycle freezes the product to -45°C at a shelf ramp of 0.5°C/min, holds for 3–4 hours, then applies primary drying at -20°C shelf temperature and 150–200 mTorr chamber pressure for 18–24 hours. Secondary drying is performed at 25°C shelf temperature and 50–80 mTorr for 6–8 hours, targeting residual moisture below 2.0% and reconstitution time not exceeding 2 minutes with 10 mL Water for Injection or 5% glucose solution. The lyophiliser is loaded to avoid edge effect; thermocouple placement in corner vials is used to monitor the slowest-drying region. After drying, vials are stoppered under partial vacuum or nitrogen, sealed with flip-off caps, and inspected for cake appearance and particulate matter. The reconstituted product contains no preservative and is intended for immediate use; admixture with calcium-containing solutions is not recommended because the polyphenolic structure can form insoluble complexes with multivalent cations. Storage is controlled below 25°C with protection from light.